Leerink Partnrs Analysts Raise Earnings Estimates for Natera

Natera, Inc. (NASDAQ:NTRA) – Equities research analysts at Leerink Partnrs increased their FY2024 EPS estimates for shares of Natera in a research note issued on Wednesday, November 13th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will post earnings per share of ($1.61) for the year, up from their prior forecast of ($1.83). The consensus estimate for Natera’s current full-year earnings is ($1.96) per share. Leerink Partnrs also issued estimates for Natera’s Q4 2024 earnings at ($0.49) EPS, Q1 2025 earnings at ($0.37) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.18) EPS and FY2026 earnings at ($0.40) EPS.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.31. Natera had a negative return on equity of 26.23% and a negative net margin of 14.01%. The business had revenue of $439.80 million during the quarter, compared to the consensus estimate of $361.43 million. During the same period in the previous year, the firm posted ($0.95) earnings per share. The business’s revenue was up 63.9% on a year-over-year basis.

Several other equities analysts have also recently commented on NTRA. Robert W. Baird raised their target price on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a research note on Wednesday. BTIG Research lifted their price target on Natera from $125.00 to $135.00 and gave the company a “buy” rating in a research report on Friday, August 9th. Canaccord Genuity Group upped their price objective on Natera from $150.00 to $165.00 and gave the company a “buy” rating in a report on Wednesday. Morgan Stanley lifted their target price on Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a report on Thursday. Finally, StockNews.com cut shares of Natera from a “hold” rating to a “sell” rating in a research report on Thursday. One analyst has rated the stock with a sell rating and seventeen have given a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $137.65.

Natera Trading Down 3.3 %

NASDAQ:NTRA opened at $146.06 on Friday. Natera has a 1 year low of $52.01 and a 1 year high of $167.79. The business has a fifty day moving average of $127.38 and a 200-day moving average of $115.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 4.01 and a current ratio of 4.39. The stock has a market cap of $19.28 billion, a price-to-earnings ratio of -82.99 and a beta of 1.53.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in Natera by 1,073.1% during the second quarter. SG Americas Securities LLC now owns 65,730 shares of the medical research company’s stock valued at $7,118,000 after purchasing an additional 60,127 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Natera by 15.1% in the 1st quarter. Russell Investments Group Ltd. now owns 74,460 shares of the medical research company’s stock valued at $6,810,000 after buying an additional 9,781 shares during the last quarter. Natixis bought a new position in Natera in the 1st quarter worth $758,000. Chartwell Investment Partners LLC lifted its position in Natera by 37.9% during the 3rd quarter. Chartwell Investment Partners LLC now owns 41,302 shares of the medical research company’s stock worth $5,243,000 after acquiring an additional 11,362 shares during the last quarter. Finally, Baader Bank Aktiengesellschaft bought a new stake in Natera during the second quarter valued at about $478,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In other news, insider Solomon Moshkevich sold 256 shares of the stock in a transaction on Tuesday, October 22nd. The shares were sold at an average price of $120.07, for a total transaction of $30,737.92. Following the transaction, the insider now owns 111,891 shares in the company, valued at $13,434,752.37. This represents a 0.23 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Gail Boxer Marcus sold 2,212 shares of Natera stock in a transaction on Thursday, November 14th. The shares were sold at an average price of $158.53, for a total transaction of $350,668.36. Following the completion of the sale, the director now directly owns 19,386 shares of the company’s stock, valued at approximately $3,073,262.58. The trade was a 10.24 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,821 shares of company stock worth $4,776,878. Corporate insiders own 7.60% of the company’s stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.